How Sleepiness Treatments Affect Blood Pressure and Thinking in Narcolepsy and Idiopathic Hypersomnia
Looks at blood pressure and thinking in people starting new sleepiness treatments.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Scottsdale, United StatesSee the site
- Trial code
- Registry title
- Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
- Status
- Enrolling by invitation
- People taking part
- 100 people, planned
- Started
- 18 May 2022
- Expected to end
- Jul 2028
- Type of study
- Observational, 3 groups
- Treatments tested
- 24-hour Ambulatory Blood Pressure Monitoring
- Oculo-Cognitive Addition Test (OCAT)
- Record updated
- 9 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narcolepsy or idiopathic hypersomnia who have been prescribed a new or different hypersomnia medicine. It studies how these medicines affect blood pressure and thinking.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Narcolepsy or idiopathic hypersomnia diagnosed using the International Classification of Sleep Disorders, third edition. BMI between 18 and 40 kg/m2.
- Earlier treatment
- A sleep specialist must have prescribed a medicine such as sodium oxybate, low sodium oxybate, pitolisant, modafinil/armodafinil, solriamfetol or a traditional stimulant. You must wait to start it until the first tests are done. People already on a stable dose of a hypersomnia medicine for at least 3 months can do the first tests while still on it. No change to medicines in the last 45 days.
Main reasons for not taking part
- Any change to medicines within the last 45 days
- Chronic alcohol or drug abuse within the prior 12 months
- Heart failure, past severe high blood pressure, or other serious heart or blood vessel disease
- Any sleep apnea treatment, such as PAP or an oral appliance, within 45 days of the first visit
- Pregnancy or breast-feeding, or taking an experimental drug in another study now or within the 28 days before screening
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Diagnosed with narcolepsy or idiopathic hypersomnia according to International Classification of Sleep Disorders, third edition
- Age 18 - 75 years
- BMI between 18 and 40 kg/m2
- Prescribed a medication of interest (e.g., sodium oxybate, low sodium oxybate, pitolisant, modafinil/armodafinil, solriamfetol, traditional stimulant(s)) by a clinical sleep specialist as part of routine medical care
- Subject must be willing to postpone starting medication until after completion of baseline assessment(s)
- If subject has been taking a prescribed hypersomnia medication(s) at a stable dose for at least 3 months and has been prescribed a new medication, then subject may complete baseline assessment(s) while taking initial hypersomnia medication(s) before starting new medication
Who cannot take part
- Any change to medication(s) within the last 45 days
- History of chronic alcohol or drug abuse within the prior 12 months
- Use of any sleep apnea treatment (e.g., Positive Airway Pressure (PAP) therapy, oral appliance therapy, etc.) within 45 days of baseline assessment visit
- Participation in another study of an investigational drug within the 28 days prior to screening visit or currently
- Heart failure, history of severe hypertension, or other cardiovascular disease compromising the patient's wellbeing or ability to participate in this study
- Pregnancy and/or breast-feeding
- Subjects who, in the opinion of the Investigator, may not be suitable for the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Mayo Clinic - ArizonaScottsdale, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is an observational study evaluating patients diagnosed with narcolepsy or idiopathic hypersomnia that have been prescribed a new/different hypersomnia treatment. The study is being done to better understand how hypersomnia treatment(s) impact blood pressure and cognitive function.
The 3 groups in the trial
- Narcolepsy Type 1
Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
Treatment: 24-hour Ambulatory Blood Pressure Monitoring and Oculo-Cognitive Addition Test (OCAT)
- Narcolepsy Type 2
Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
Treatment: 24-hour Ambulatory Blood Pressure Monitoring and Oculo-Cognitive Addition Test (OCAT)
- Idiopathic Hypersomnia
Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
Treatment: 24-hour Ambulatory Blood Pressure Monitoring and Oculo-Cognitive Addition Test (OCAT)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
- Plain-language title
- How Sleepiness Treatments Affect Blood Pressure and Thinking in Narcolepsy and Idiopathic HypersomniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05371483, who can take part
- Record updated
- 9 June 2026